Walleye Capital
NTLA icon

Walleye Capital’s Intellia Therapeutics NTLA Stock Holding History

Walleye Capital’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,580
Closed -$83.8K – 4792
2025
Q4 		$59.2K Buy
+6,580
New +$90.6K ﹤0.01% 4041
2025
Q3 		– Sell
-29,948
Closed -$369K – 4924
2025
Q2 		$281K Sell
29,948
-11,524
-28% -$94.6K ﹤0.01% 3095
2025
Q1 		$295K Sell
41,472
-142,600
-77% -$1.44M ﹤0.01% 2970
2024
Q4 		$2.15M Buy
184,072
+113,043
+159% +$1.76M 0.01% 1724
2024
Q3 		$1.46M Buy
71,029
+15,874
+29% +$366K ﹤0.01% 2258
2024
Q2 		$1.23M Buy
55,155
+49,647
+901% +$1.18M ﹤0.01% 2615
2024
Q1 		$152K Sell
5,508
-197,819
-97% -$5.49M ﹤0.01% 4153
2023
Q4 		$6.2M Buy
203,327
+19,872
+11% +$571K 0.01% 965
2023
Q3 		$5.8M Buy
+183,455
New +$7.12M 0.01% 922
2023
Q2 		– Sell
-127,504
Closed -$5.17M – 4713
2023
Q1 		$4.75M Buy
127,504
+32,080
+34% +$1.26M 0.07% 344
2022
Q4 		$3.33M Buy
95,424
+77,163
+423% +$3.67M 0.06% 383
2022
Q3 		$1.02M Buy
+18,261
New +$1.13M 0.02% 950
2022
Q2 		– Sell
-50,521
Closed -$3.67M – 2610
2022
Q1 		$3.67M Buy
50,521
+43,147
+585% +$3.66M 0.1% 219
2021
Q4 		$872K Buy
+7,374
New +$924K 0.03% 674
2020
Q2 		– Sell
-1,485
Closed -$18K – 858
2020
Q1 		$18K Sell
1,485
-1,112
-43% -$15K ﹤0.01% 761
2019
Q4 		$38K Sell
2,597
-924
-26% -$12.9K ﹤0.01% 1543
2019
Q3 		$47K Buy
+3,521
New +$56.1K ﹤0.01% 1617

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Walleye Capital's NTLA Position: Q1 2026 in Review

Walleye Capital sold out of Intellia Therapeutics (NTLA) in Q1 2026, closing a stake of 6,580 shares — an estimated $83.8K sold.

Walleye Capital first reported a position in NTLA in Q3 2019 and held it in 17 quarters. The position peaked at $6.2M in Q4 2023. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Walleye Capital reported no remaining Intellia Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Walleye Capital sold 6,580 Intellia Therapeutics shares in Q1 2026, an estimated $83.8K.
  • Walleye Capital first reported a position in Intellia Therapeutics in Q3 2019 and held it in 17 quarters.
  • Walleye Capital's Intellia Therapeutics position peaked at $6.2M in Q4 2023.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.